Author Archives: Mari Serebrov

You’ve come a long way, baby, but still a long way to go

Patients have come a long way to get a say in the drug development and approval process. But there’s still some ground to cover if they’re going to move from the passive subject role to a 50-50 partnership that reminds…

Share

Patient engagement as important as the data

The thought of having unfettered access to all the medical and genomic data of a million Americans had researchers gathered at the National Institutes of Health’s first workshop on precision medicine licking their lips. Almost giddy with excitement, they contemplated…

Share

Listening to the voice that matters

Since being diagnosed with cancer a few months ago, I have been in an unwanted crash course on the patient perspective of everything I’ve been writing about biopharma for the past several years. It’s an eye-opener. Genetic testing, lack of…

Share

Emerging biosimilar market knows no parallel

It’s not every day that drugmakers get a chance to take on an entirely new market. Biosimilars are offering that opportunity. And hundreds of drugmakers, research institutions and governments are hoping to make the most of it. The result is…

Share

Ebola is raging like a wildfire

Testifying in a joint Senate committee hearing on Ebola this week, the CDC’s Beth Bell compared the epidemic spreading through West Africa with a forest fire. She stressed that any ember left undetected could quickly flare up and re-ignite the…

Share

Old news, yet still making headlines

High drug prices are old news. Old, as in 19th century old. But that doesn’t mean they aren’t breaking news today. Breaking, as in breaking the family budget. One of the speakers at the Institute of Medicines National Cancer Policy…

Share

Let the conversation begin

“Communication about how certain treatments are working in certain patients is happening through a multitude of media around the globe. These conversations between and among doctors, patients, researchers, and scientists in academia and industry should be facilitated. This includes the…

Share

Hamburg: Society needs to weigh in

Including the patient voice in the drug approval process could produce a fundamental shift in the risk-benefit equation of a new drug. But first, the FDA has to figure out how to do it, and that may take a broader…

Share

Biosimilar regulation: 1984 v. 2014

It’s 1984. The year opens with the demise of Ma Bell, as the Bell System is broken into smaller, regional telephone companies. The idea is to end Ma’s nationwide monopoly, but the result is a handful of smaller monopolies since there…

Share

It’s How You Look at the Vial

What’s in a biosimilar name? That depends on whether the vial is half empty or half full. Seeing it as half full, many generic makers focus on the similarities between a follow-on and its reference biologic. Because of those similarities,…

Share